Purchase Order 36C24419P0712
Award Date
6/27/19
Potential Completion Date
10/31/19
Potential Value
$79K
Federal Agency
Veterans Integrated Service Network 4
Awardee
Accredo Health Group, Inc.
Ultimate Awardee
Not listed
NAICS Category
446110 - Pharmacies and Drug Stores
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bartlett, TN 38134, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price purchase order contract to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, to provide OXERVATE 0.002% eye drops. The contract has a potential value of $149,388.16 and a completion date of June 30, 2023. As a prime contractor, Accredo Health Group supports the VHA by delivering specialty pharmaceutical products to VA medical centers and facilities nationwide....
The U.S. Department of Veterans Affairs (VA) awarded a firm fixed-price purchase order contract to Accredo Health Group, Inc., a subsidiary of Express Scripts, to provide OXERVATE 0.002% OPTH DROPS 1 ML 7'S 7ML 2 PACK, a specialty pharmaceutical product. The $74,694.08 contract has an ultimate completion date of March 31, 2025 and was awarded on January 10, 2023 through the VA's Veterans Integrated Service Network 21 (VISN 21). The contract is not designated as a set-aside. Accredo Health Group,...
This is a $40,697.68 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the supply of specialty pharmaceutical products, including medications to treat pulmonary arterial hypertension, neuropathic lysosomal storage disorders, and ophthalmic disorders. The contract has an ultimate completion date of March 14, 2025 and is part of the VA's Veterans...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) to Dompe U.S. Inc., a foreign-owned pharmaceutical manufacturer, to provide Oxervate (cenegermin-bkbj) 0.002% ophthalmic solution. The $39,774.12 order was placed against Dompe's existing General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract (FSS-61-IB). Oxervate is an ophthalmic product used to treat neurotrophic keratitis. This order does not have a set-aside designation....
The Department of Veterans Affairs (VA) awarded a firm fixed-price purchase order contract to Accredo Health Group, Inc., a for-profit pharmacy benefit management company specializing in specialty pharmaceutical services. The $10,708.63 contract is for the emergency purchase of sodium oxybate, a medication used to treat certain medical conditions. The contract has a completion date of March 28, 2025 and is part of the VA's Veterans Integrated Service Network 12 (VISN 12) program, which...
This is a $103,003.20 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company specializing in specialty pharmaceutical services. The contract is for the delivery of various complex and high-value medications, primarily to support the VA's Veterans Integrated Service Network (VISN) healthcare facilities. Key medications provided under this contract include drugs used to treat...
This delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule, awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20, is for $72,120.32 of OXERVATE 0.002% ophthalmic solution. The prime contractor is Dompe U.S. Inc. located in San Mateo, California, where the place of performance will be. The completion date is December 20, 2022. No set-aside designation was used for this contract. The pricing is firm fixed...
The U.S. Department of Veterans Affairs, through the Veterans Integrated Service Network 1, awarded a Firm Fixed Price Blanket Purchase Agreement (BPA) call to Dompe U.S. Inc., a foreign-owned pharmaceutical manufacturer, to provide Oxervate ophthalmic solution medication. The contract, valued at $70,914.40, is funded through the VA's pharmaceutical and drugs acquisition schedule (FSS-61-IB). Dompe U.S. Inc. has provided Oxervate and other pharmaceutical products to the VA through various...
The Department of Veterans Affairs Veterans Health Administration awarded a $149,388 firm fixed price delivery order against GSA Schedule Pharmaceuticals and Drugs (FSS-61-IB) to Dompe U.S. Inc. for OXERVATE 0.002% solution. Performance will take place in Bartlett, Tennessee over approximately two months concluding in late September 2023. As part of its mission to provide healthcare services to veterans, VA-VHA Network 5 will utilize this contract to procure an ophthalmic solution from the prime...
This federal contract award, valued at $80,409.58, was issued by the Department of Veterans Affairs' Veterans Integrated Service Network 19 (VISN 19) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company and subsidiary of Express Scripts. The contract is a firm fixed-price purchase order for the delivery of 9 pharmacy orders across multiple VISN locations, including medications to treat conditions such as pulmonary arterial hypertension, neuropathic lysosomal storage...